[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100342205":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":29,"centralContacts":34,"locations":44,"responsibleParty":59,"collaborators":61,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":39,"maxAge":39,"enrollmentInfo":71,"targetDuration":39,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":47,"whyStopped":39,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University of Oulu","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ketamine","EXPERIMENTAL","Individuals needing the LISA will receive premedication as follows: caffeine (in case of gestational age \\\u003C32 weeks and not already given), glycopyrrolate, and randomly either ketamine or fentanyl.",[13],"Drug: Ketamine",{"label":15,"type":10,"description":11,"interventionNames":16},"Fentanyl",[17],"Drug: Fentanyl",[19,25],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Individuals will receive randomly either ketamine or fentanyl as a premedication",[9],[24],"Ketanest-S",{"type":20,"name":15,"description":21,"armGroupLabels":26,"otherNames":27},[15],[28],"Fentanyl-Hamel",[30],{"name":31,"affiliation":32,"role":33},"Riitta Marttila, MD, docent","Oulu University and Oulu University Hospital","PRINCIPAL_INVESTIGATOR",[35,41],{"name":36,"role":37,"phone":38,"phoneExt":39,"email":40},"Eveliina Ronkainen, MD, PhD","CONTACT","+358 8 3152011",null,"eveliina.ronkainen@oulu.fi",{"name":42,"role":37,"phone":38,"phoneExt":39,"email":43},"Antti Härmä, MD","aharma@paju.oulu.fi",[45],{"facility":46,"status":47,"city":48,"state":39,"zip":39,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Oulu University Hospital","RECRUITING","Oulu","Finland","FI",{"type":52,"coordinates":53},"Point",[54,55],25.46816,65.01236,{"lat":55,"lon":54},[58],{"name":36,"role":37,"phone":39,"phoneExt":39,"email":39},{"type":60,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR",[62],{"name":46,"class":6},"100342205","phase-4-premedication-for-less-invasive-surfactant-administration-100342205",false,"NCT03735563","Premedication for Less Invasive Surfactant Administration","LISA-Med","Inclusion Criteria:\n\n* Gestational age at birth ≥26 weeks\n* Respiratory insufficiency managed with non-invasive respiratory support (nasal continuous positive airway pressure or high-flow)\n* Requirement for oxygen to maintain oxygen saturation in the target range and need for surfactant treatment (according to clinician's assessment)\n* If further doses of surfactant are needed, patient can be re-randomized\n\nExclusion Criteria:\n\n* Severe RDS with high oxygen requirements, severe respiratory acidosis and\u002For widespread atelectasis radiologically, such that ongoing ventilator support will be necessary after surfactant therapy (intubation in preferable to LISA if FiO2 \\>40% at GA \\\u003C28 weeks and \\>60% at GA ≥28 weeks)\n* Maxillo-facial, tracheal or known pulmonary malformations\n* Any known chromosomal abnormality or severe malformation\n* An alternative cause for respiratory distress (e.g. congenital pneumonia or pulmonary hypoplasia)","ALL",{"count":72,"type":73},40,"ESTIMATED","INTERVENTIONAL",[76],"PHASE4","Early respiratory management of preterm infants immediately after birth should be as gentle as possible. With this so-called developmental approach, unnecessary invasive methods can be avoided or at least postponed. This kind of \"soft landing\" allows cardiorespiratory transition with fewer adverse outcomes. Less invasive surfactant administration (LISA) is a technique that involves delivery of surfactant to a spontaneously breathing infant through a thin catheter. This technique minimizes the risk for neonatal lung injury caused by positive pressure ventilation. LISA is nowadays widely used in neonatal intensive care units (NICU). Although less invasive, newborns exposed to this procedure need premedication prior the procedure. There is no consensus, which drug would be the optimal premedication for LISA and the research on this topic is lacking. An ideal premedication would treat the procedural pain without suppressing the infant's own breathing. The sedation and analgesia should start fast but the effect should be short-acting with as few adverse effects as possible. The aim of this randomized, controlled trial (RCT) is to evaluate the feasibility, efficacy and safety of LISA protocol with the premedication of either ketamine or fentanyl by investigating whether one or the other is associated with lower rate of adverse events, hence would be preferred choice for premedication protocol.",[79],"Surfactant Deficiency Syndrome Neonatal",[81,82],"less invasive surfactant administration","premedication","2023-06-02",{"date":85,"type":86},"2023-06-05","ACTUAL",{"date":88,"type":86},"2019-02-11",{"date":90,"type":73},"2026-10-31",{"name":5,"class":6},1]